Alpha 2.0
Login Register
» Authors » D Crivellari

D Crivellari

Explore the profile of D Crivellari including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 90
Citations 958
Followers 0
Related Specialties
Oncology
General Medicine
Hematology
Top 10 Co-Authors
A Veronesi
E Galligioni
S Tumolo
A Goldhirsch
S Frustaci
R D Gelber
S Monfardini
U Tirelli
M D Magri
B Thurlimann
Published In
Ann Oncol
Tumori
Eur J Cancer
Cancer Treat Rep
Br J Cancer
Affiliations
Soon will be listed here.
Recent Articles
11.
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
Viale G, Giobbie-Hurder A, Gusterson B, Maiorano E, Mastropasqua M, Sonzogni A, et al.
Ann Oncol . 2009 Jul; 21(2):245-254. PMID: 19633051
Background: Peritumoral vascular invasion (PVI) may assist in assigning optimal adjuvant systemic therapy for women with early breast cancer. Patients And Methods: Patients participated in two International Breast Cancer Study...
12.
Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer
Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, et al.
Cancer Chemother Pharmacol . 2009 Feb; 64(4):673-80. PMID: 19184601
Purpose: Combination of intravenous (i.v.) vinorelbine and capecitabine was shown to be feasible and effective in metastatic breast cancer (MBC). In an effort to improve patient convenience and to prolong...
13.
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer
Puglisi F, Cardellino G, Crivellari D, Di Loreto C, Magri M, Minisini A, et al.
Ann Oncol . 2008 Apr; 19(9):1541-6. PMID: 18441329
Background: Preclinical data have indicated a synergistic interaction between docetaxel and capecitabine by means of taxane-induced up-regulation of thymidine phosphorylase (TP). On the basis of such premises, we conducted a...
14.
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
Gruber G, Cole B, Castiglione-Gertsch M, Holmberg S, Lindtner J, Golouh R, et al.
Ann Oncol . 2008 Apr; 19(8):1393-1401. PMID: 18385202
Background: Extracapsular tumor spread (ECS) has been identified as a possible risk factor for breast cancer recurrence, but controversy exists regarding its role in decision making for regional radiotherapy. This...
15.
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, et al.
Ann Oncol . 2007 Jan; 18(4):701-8. PMID: 17237474
Background: We evaluated the ability of CA15-3 and alkaline phosphatase (ALP) to predict breast cancer recurrence. Patients And Methods: Data from seven International Breast Cancer Study Group trials were combined....
16.
Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study
Sorio R, Toffoli G, Crivellari D, Bearz A, Corona G, Colussi A, et al.
J Chemother . 2006 Jun; 18(2):188-91. PMID: 16736888
Seventeen elderly patients with advanced progressive non small cell lung cancer (NSCLC) were treated with oral etoposide at the daily dose of 100 mg for 14 days every 3-4 weeks...
17.
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
Pestalozzi B, Zahrieh D, Price K, Holmberg S, Lindtner J, Collins J, et al.
Ann Oncol . 2006 Apr; 17(6):935-44. PMID: 16603601
Background: We sought to determine whether a high-risk group could be defined among patients with operable breast cancer in whom a search of occult central nervous system (CNS) metastases was...
18.
Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring
Crivellari D, Lombardi D, Corona G, Massacesi C, Talamini R, Sorio R, et al.
Ann Oncol . 2006 Feb; 17(5):807-12. PMID: 16497825
Background: To determine if protracted low-dose oral idarubicin (IDA), feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast...
19.
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
Nitti D, Wils J, Guimaraes dos Santos J, Fountzilas G, Conte P, Sava C, et al.
Ann Oncol . 2005 Nov; 17(2):262-9. PMID: 16293676
Background: In patients who underwent radical resection for gastric cancer, we investigate the relative efficacy of combined 5-fluorouracil+adriamycin or epirubicin and methotrexate with leucovorin rescue (FAMTX or FEMTX) compared with...
20.
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
Pagani O, Sessa C, Nole F, Munzone E, Crivellari D, Lombardi D, et al.
Ann Oncol . 2005 Jul; 16(10):1609-17. PMID: 15994176
Background: The efficacy and safety of prolonged fluoropyrimidines, either intravenously or orally, prompted their integration with taxanes and anthracyclines in the treatment of advanced breast cancer (ABC). We conducted three...